Every year, World Toilet Day is observed to raise awareness about the global sanitation crisis and encourage action to solve it. The goal set by the United Nation is to achieve safe toilets for all by 2023, as a part of their Sustainable Development Goals.
The UN also states that 3.5 billion people live without proper sanitation and many children also lose their lives due to poor sanitation and unsafe water. This is why World Toilet Day is observed to raise awareness on this issue.
This year, the theme for World Toilet Day 2024 is "Toilets - A Place for Peace'. This focuses on the growing threat to sanitation that is caused by conflict, climate change, disaster and neglect. When there is a threat to using toilets, it can lead to many health risks.
Not using toilets for too long may lead to Urinary Tract Infection or UTI. For many who do not have access to clean toilets do not drink enough liquid or hold pee for too long. Doctors suggest that holding in pee for too long can cause bacteria to multiply and lead to UTI. By not drinking enough water, your bladder fails to tell the body to pee often, and can cause the bacteria to spread through the urinary tract, which can lead to infection.
Holding in pee for too long can also cause your bladder to stretch, making it difficult or even impossible for the bladder to contract and release pee normally. It can also damage your pelvic floor muscles or could lead to kidney stones.
To prevent such conditions, it is important that everyone has access to clean and safe toilets. In terms of history, the day was established in 2001, by the World Toilet Organization (WTO), which was founded by Jack Sim. However, it was officially recognised by the UN in 2013. The Government of Singapore worked with WTO to create the first UN resolution called Sanitation for All.
India too promotes safe and hygiene toilet through its Swachh Bharat Yojna.
Credit: AI-generated image
The World Health Organization (WHO) has issued a global medical product alert after identifying falsified batches of the cancer medicine DARZALEX (daratumumab). It also issued a warning that the counterfeit products could cause serious health risks to patients and disrupt the treatment process.
The WHO issued an alert against the circulation of falsified DARZALEX (daratumumab). The incident came to light in May and June 2026. According to the WHO, the falsified injections were found in the Maldives and Mexico after being supplied by unauthorised distributors.
In at least one reported case, hospitals received fake medication, prompting international concern over gaps in the pharmaceutical supply chain.
DARZALEX (daratumumab) is an antibody that is used to treat multiple myeloma, cancer of plasma cells in the bone marrow, as well as amyloid light-chain (AL) amyloidosis, a rare blood disorder.
The drug plays a crucial role in the treatment of various types of cancer. That is why the WHO said that the circulation of its compromised version could cause delayed therapy, treatment failure, and potentially life-threatening consequences.
Read more: Why Sustainable Weight Loss Requires More Than Cutting Calories
WHO said the fake products deliberately misrepresent their identity, composition, or source. The manufacturer, Janssen, confirmed that the batch numbers MYS7381 and STV1K01 are not valid, and any DARZALEX product bearing these batch numbers should be considered falsified and must not be used.
The Maldives Food and Drug Authority also reported visible particulate matter inside vials from one of the counterfeit batches.
The UN health agency has urged national regulatory health bodies, healthcare providers, wholesalers, and distributors to strengthen security across the pharmaceutical supply chains to prevent the infiltration of counterfeits.
It also advised countries to closely monitor unregulated pharmaceutical markets, where counterfeit medicines are more likely to circulate.
Read more: ICMR & IIT Bombay Create Placenta-On-Chip To Study Pregnancy Disorders & Drug Safety
WHO issued precautionary measures to avoid purchasing falsified medications:
The latest warning adds to a growing list of WHO medical product alerts involving counterfeit cancer medicines.
In recent years, the WHO has issued alerts for various falsified cancer drugs including IMFINZI (durvalumab), IBRANCE (palbociclib) and DEFITELIO (defibrotide), highlighting the growing threat of counterfeit medicines that could disrupt life-saving treatment courses.
The WHO estimates that more than one in ten medical products in underdeveloped and developed countries are either substandard or falsified, making poor-quality medicines one of the world's major public health challenges.
Credit: AI-generated image
Indian scientists from ICMR-NIRWoH and IIT Bombay have developed "placenta-on-chip" platform that mimics key functions of the human placenta. The indigenous innovation could transform maternal and fetal health studies while reducing dependence on animal testing.
In a major breakthrough for pregnancy and fetal health research, Indian scientists have developed an indigenous “placenta-on-chip" platform that successfully mirrors several important functions of the human placenta.
According to the journal Biofabrication, the platform, developed by researchers from the ICMR-National Institute for Research on Women's Health (ICMR-NIRWoH) in collaboration with IIT Bombay, will equip scientists with a new tool to study pregnancy in depth, understand complications, and evaluate the safety of medicines during pregnancy.
Also read: WHO Unveils Global Action Plan To Combat Rising Fungal Infections And Drug Resistance
The placenta is a temporary organ that develops during pregnancy and acts as the lifeline between the mother and the unborn baby.
It provides unborn babies with oxygen and nutrients, eliminates waste products, produces hormones essential for pregnancy, and serves as a protective barrier for the baby.
Despite its vital role in the development of a healthy baby, the placenta remains one of the least understood human organs because its research during pregnancy is both ethically and technically challenging.
The placenta-on-chip operates like a laboratory platform, recreating the interface between the mother and the fetus using living human cells. It reproduces several essential functions of the placenta, including:
Researchers also demonstrated that the platform could simulate hyperglycaemic conditions similar to gestational diabetes, allowing scientists to study how pregnancy-related diseases affect placental function.
The placenta-on-chip platform could significantly improve research into pregnancy complications like:
Also read: Cancer Survivorship Beyond Treatment: Why Caregiver Support Must Become A Standard Of Oncology Care
Scientists also believe it could become an important tool for evaluating whether medicines can cross the placental barrier, helping researchers identify drugs that are safer during pregnancy.
Pregnant women are often excluded from clinical drug trials because of ethical concerns, leaving doctors with limited research. Placenta-on-chip may help bridge this gap.
Another major advantage is its potential to reduce dependency on animals for testing. Animal studies do not always accurately reflect how the human placenta functions because placenta structures differ significantly across species. Human cell-based platforms can therefore provide more clinically relevant insights and findings.
The researchers believe the placenta-on-chip could become an important platform for studying maternal-fetal health, testing new therapies, and understanding how various complications develop during pregnancy. The innovation is a step towards establishing clinically safe procedures to tackle pregnancy-related complications.
The technology has the potential to contribute not only to safer pregnancies but also to more reliable, human-based research that could benefit global healthcare. India could progress significantly in biomedical research, influencing and advancing reproductive healthcare systems worldwide.
Credit: AI-generated image
The World Health Organization (WHO) has released a new global plan, urging countries to improve their response to the growing risk of fungal diseases and antifungal resistance. The health and disease regulatory body warned that the issue has been left unaddressed since a long time despite its serious impact on public health.
According to the WHO, fungal diseases affect more than 300 million people worldwide every year. It also said that they are responsible for serious complications, prolonged hospitalisation, and high mortality, particularly among those with weakened immune systems.
Despite the risks, fungal infections continue to receive far less attention than bacterial or viral diseases. They are also missing from national health strategy planning, particularly in antimicrobial resistance (AMR) plans.
Why Antifungal Resistance Is A Global Concern?
Antifungal resistance happens when fungi grow, resisting medicines used to treat the infections. This makes it harder and sometimes impossible to cure infections.
The WHO said resistance to antifungal drugs is being fueled by:
Also read: The High Cost of Ignoring Fungi: The Hidden Burden of Invasive Fungal Infections
Dr Jean Pierre Nyemazi, Acting Director of WHO's Department of Antimicrobial Resistance said, “The Updated Global Action Plan on AMR approved by the Seventy-ninth World Health Assembly recognized that antifungal resistance is an integral part of the AMR challenge and one we can no longer afford to overlook. This Blueprint gives countries a concrete path forward.”
What Does The WHO Blueprint Outline?
The blueprint to fight fungal infections has been developed with input from more than 150 experts across WHO regions, including specialists in infectious diseases, diagnostics, surveillance, public health and patient advocacy. It builds on the WHO's fungal priority pathogens list released in 2022, which identified the most dangerous fungal pathogens threatening human health.
The guidance outlines four priority areas for countries to strengthen their response. These include:
The WHO has also identified 12 key areas to help governments prioritise investments and integrate fungal disease surveillance into existing healthcare systems.
WHO officials said fungal diseases continue to be neglected across national health policies despite their growing burden.
Hatim Sati, Technical Officer in WHO's Department of Antimicrobial Resistance, who led the blueprint's development, said, “Fungal disease and antifungal resistance remain an under-addressed priority across national health plans, AMR strategies, and surveillance systems. This Blueprint provides countries with a practical framework to strengthen their response.”
© 2024 Bennett, Coleman & Company Limited